1st RRMS Patient Dosed in Trial of Immunotherapy & MS News That Caught Ed Tobias' Attention

Multiple Sclerosis News Today’s multimedia associate, Price Wooldridge, reads a news article about how a Phase 1/2 clinical trial has begun dosing with IMCY-0141, Imcyse’s targeted immunotherapy to slow progression of relapsing-remitting MS.

He also reads “MS News That Caught My Eye Last Week: Deep Brain Stimulation, IMCY-0141, Foralumab, Vumerity,” a column by Ed Tobias.

===================================

Are you interested in learning more about multiple sclerosis? If so, please visit:
https://multiplesclerosisnewstoday.com/
=====================================
To join in on conversations regarding multiple sclerosis, please visit:
https://multiplesclerosisnewstoday.com/forums/